Prothena Corporation plc Release: First Human Dosed In Phase 1 Study Of PRX002 For Treatment Of Parkinson's Disease
4/9/2014 8:55:14 AM
DUBLIN, Ireland, April 8, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today the successful start of a Phase 1 clinical trial of its therapeutic monoclonal antibody candidate, PRX002, for the treatment of Parkinson's disease. Prothena has earned a $15 million milestone payment from Roche related to the initiation of this study.
Help employers find you! Check out all the jobs and post your resume.
comments powered by